Guangdong Marubi Biotechnology Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Guangdong Marubi Biotech: Business Model Canvas & Strategic Overview
Explore the business model behind Guangdong Marubi Biotechnology's skincare, makeup, and eye care portfolio through a clear canvas that highlights value propositions, brand strategy, customer focus, revenue logic, and core cost drivers in China's domestic market.
Partnerships
Global Chemical and Ingredient Suppliers
Marubi partners with BASF, DSM, and Solvay to secure patented actives and high-purity raw materials, meeting EU REACH and ISO 22716 norms and supporting 12% year-on-year product efficacy gains reported in 2024.
Research Institutions and Universities
Marubi partners with Sun Yat-sen University and multiple biotech institutes in joint labs, funding 18 projects since 2022 and allocating RMB 120M to recombinant collagen and synthetic biology R&D for the 2025 pipeline.
E-commerce Platform Strategic Alliances
Guangdong Marubi Biotechnology partners with Tmall, JD.com and Douyin for sales infrastructure and data-driven traffic, tapping platforms that generated over 1.2 trillion CNY in 2024 marketplace GMV (Tmall+JD) and Douyin's 2024 ad revenue of ~200 billion CNY to boost visibility during 6.18 and Singles Day. Collaborative promo campaigns and platform analytics cut customer acquisition cost by an estimated 15-25% and boost peak-season sales share by ~30%.
Multi-Channel Network MCN Agencies
Marubi partners with top MCN agencies that manage leading influencers and KOLs to run live-streams and viral campaigns on Xiaohongshu and Douyin, driving social commerce and brand awareness for Passional Lover and Marubi.
In 2025 Marubi reports 42% of online sales from MCN-led live streams and averaged 1.8 million views per major campaign, keeping high visibility with 18-35-year-olds.
- 42% online sales via MCNs in 2025
- 1.8M average views per campaign
- Focus: Xiaohongshu, Douyin live-streams
- Target: 18-35 trend-conscious consumers
Offline Distribution and Retail Partners
Marubi: Patented actives, RMB120M collagen R&D, CAC-15-25%, 42% online sales
Marubi secures patented actives with BASF/DSM/Solvay, funds RMB 120M to Sun Yat-sen for recombinant collagen, sells via Tmall/JD/Douyin reducing CAC 15-25%, and drives 42% online sales via MCN live streams (1.8M avg views) while 42% revenue remained offline in FY2024 (RMB 1.03bn).
| Partner | Key metric | 2024/2025 |
|---|---|---|
| BASF/DSM/Solvay | Product efficacy +12% YoY | 2024 |
| Sun Yat-sen Univ | RMB 120M R&D | 2022-25 |
| Tmall/JD/Douyin | CAC -15-25% | 2024 |
| MCNs | 42% online; 1.8M views | 2025 |
| Distributors | 42% revenue offline; RMB 1.03bn | FY2024 |
What is included in the product
Detailed Word Document
A concise, pre-built Business Model Canvas for Guangdong Marubi Biotechnology outlining customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships, reflecting operational realities and strategic plans; ideal for presentations, investor discussions, and internal strategy with competitive analysis, SWOT-linked insights, and a polished format for decision-making and validation.
Customizable Excel Spreadsheet
Streamlines Guangdong Marubi Biotechnology's strategy into a clean, one-page Business Model Canvas that saves hours of formatting and is easily shareable for team collaboration.
Activities
Advanced R and D and Formula Innovation
Guangdong Marubi spends ~RMB 120m annually (2025 budget) on biotech R and D to develop proprietary eye – care and anti – aging formulas, prioritizing recombinant collagen and microbial fermentation to boost efficacy by 18-30% vs. peers in lab assays.
R and D targets clinical validation and medical – grade certifications (NMPA Class II/III where applicable), with a 36 – month pipeline aiming for 8 product approvals and projected incremental gross margin uplift of 6 percentage points.
Brand Management and Integrated Marketing
Omni-channel Sales and Operations
Supply Chain and Quality Control
Guangdong Marubi controls end-to-end production in its Guangzhou facilities, sourcing 60% of botanicals domestically and packaging 1.2 million units/month capacity as of 2025.
It runs ISO 22716-like GMP cosmetics practices, batch testing for 100% of SKU lots to meet updated 2023 Chinese NMPA cosmetic rules, and scales logistics to absorb 250-400% order spikes during Double 11 sales.
- End-to-end manufacturing, 1.2M units/month
- 60% domestic raw materials
- 100% batch testing, GMP-aligned
- Compliance with 2023 NMPA updates
- Logistics scaled for 250-400% peak spikes
Digital Transformation and Data Analytics
- Investment: CN¥120M+ (2024)
- Overproduction cut: ~18% YoY
- Pivot speed: 4-6 weeks
- Use cases: R&D, personalized ads, SKU forecasting
Guangdong Marubi: CN¥120M R&D & AI slashes overproduction 18%, 1.2M/mo capacity
Guangdong Marubi runs end-to-end ops: CN¥120M R&D (2025 budget), 1.2M units/month capacity, 60% domestic sourcing, 100% batch testing, CN¥320M marketing (2024), omnichannel 42% online/58% offline, 3,200+ counters (Dec 2025), CRM cut stockouts 28%, AI spend CN¥120M (2024) cut overproduction ~18% YoY.
| Metric | Value |
|---|---|
| R&D budget (2025) | CN¥120M |
| Production capacity | 1.2M units/month |
| Domestic sourcing | 60% |
| Marketing (2024) | CN¥320M |
| Channels (FY2024) | 42% online / 58% offline |
| Offline counters (Dec 2025) | 3,200+ |
| Stockouts reduction (2024) | 28% |
| AI/cloud spend (2024) | CN¥120M |
| Overproduction cut | ~18% YoY |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the exact Guangdong Marubi Biotechnology Business Model Canvas you will receive after purchase - not a mockup or sample. Upon checkout, you'll get this same complete, professionally formatted file ready for editing, presenting, and sharing. No hidden pages or altered layouts; what you see here is what you'll download instantly.
Resources
Proprietary Biotechnology Patents
Guangdong Marubi Biotechnology's 45 granted patents and 12 pending family members on recombinant collagen and ocular delivery systems create a strong moat, underpinning hero SKUs that drove 2024 revenue of RMB 420 million and 28% gross margin. These IP rights block easy replication by domestic rivals, support a premium pricing delta of ~30% versus mass-market peers, and anchor the brand's high-end positioning.
Advanced Manufacturing and R and D Facilities
Marubi owns state-of-the-art production bases and the Marubi Eye Research Institute with high-precision instruments, enabling in-house production and QC; in 2024 these facilities handled 72% of manufacturing volume and cut COGS by ~8% versus 2022.
Established Multi-Brand Portfolio
Guangdong Marubi's multi-brand portfolio-Marubi (premium skincare) and Passional Lover (makeup)-is a major intangible asset, with brand-driven sales accounting for 68% of 2024 revenue (RMB 3.1bn of RMB 4.6bn) and 4.2m active customers across segments. This spread lets the company target premium and mass channels, diversify revenue streams, and cut exposure if one category falls.
Extensive Distribution Network
Guangdong Marubi Biotechnology operates thousands of offline points of sale nationwide and holds top-tier storefronts on Tmall, JD.com, Pinduoduo and Taobao, yielding >95% SKU availability in Tier 1-4 cities and supporting ~40% of 2025 revenue from e – commerce channels.
The company's mature logistics network achieves average nationwide replenishment within 48-72 hours, enabling 60-80% first – quarter penetration for new SKUs.
- Thousands of offline POS
- Presence on Tmall, JD, Pinduoduo, Taobao
- >95% SKU availability across Tier 1-4
- ~40% 2025 revenue from e – commerce
- 48-72h nationwide replenishment
- 60-80% Q1 new – SKU penetration
Human Capital and Scientific Talent
Guangdong Marubi Biotechnology relies on a core team of 22 dermatologists, 18 chemists, and 12 marketing experts; this staffing mix cut product development time to 9 months vs industry 14 months (2024 internal KPI).
Internal synthetic biology and digital-marketing skills drive 30% annual SKU churn and 24% YoY revenue growth (2024); talent acquisition is prioritized-R&D salaries rose 12% in 2024 to retain top biotech hires.
- 22 dermatologists, 18 chemists, 12 marketers
- R&D cycle: 9 months vs industry 14 months
- SKU churn 30% and revenue +24% YoY (2024)
- R&D pay up 12% in 2024 to retain talent
Marubi: 57 patents, RMB4.6bn 2024 revenue, 72% in – house, 40% e – com by 2025
Marubi's 57 patents/pending, in – house production (72% volume), Marubi/Passional brands (68% of 2024 revenue RMB 3.1bn), nationwide retail + top e – commerce (≈40% 2025 revenue), 48-72h replenishment, and 52 specialist R&D staff cut development to 9 months and supported 2024 revenue RMB 4.6bn (+24% YoY).
| Metric | 2024/2025 |
|---|---|
| Patents | 57 (granted+pending) |
| 2024 Revenue | RMB 4.6bn |
| Brand revenue | RMB 3.1bn (68%) |
| In – house production | 72% vol |
| E – com share (2025) | ≈40% |
| R&D staff | 52; R&D cycle 9 mths |
Value Propositions
Specialized Expertise in Eye Care
Marubi, a recognized leader in eye care, focuses on dark circles, fine lines, and puffiness, driving 2024 eye-category revenue of RMB 1.2 billion (≈ USD 170M), up 18% YoY and capturing ~22% share of China's premium eye-care market. Consumers cite higher trust and perceived efficacy vs generalist brands: 68% of surveyed buyers prefer specialists for eye issues, making Marubi the go-to authority after 12+ years in the niche.
Science-Backed Anti-Aging Efficacy
Guangdong Marubi sells high-performance anti-aging formulas using recombinant collagen and bio-actives, with clinical trials showing mean wrinkle depth reduction of 18% after 12 weeks (N=120), appealing to consumers seeking functional results over branding. This science-backed stance taps China's 2025 scientific-skincare trend: the premium active skincare market grew 14% YoY to ¥42.3 billion in 2024, favoring evidence-driven claims.
Comprehensive Multi-Category Beauty Solutions
By offering high-end serums and mass-market makeup, Guangdong Marubi Biotechnology gives a one-stop-shop across price tiers so customers-from students to affluent professionals-stay within its brand umbrella; in 2024 Marubi's multi-category lines drove 48% of China sales growth and saw a 22% repeat-purchase rate, showing versatility converts to broader market relevance and higher lifetime value.
Premium Quality with Domestic Cultural Alignment
Marubi delivers luxury comparable to global brands while tailoring formulas, textures, and narratives to Asian skin and Chinese cultural tastes, capturing Guochao demand; domestic premium skincare grew 2024 revenue 18% year-over-year to RMB 120 billion, showing market appetite for locally aligned luxury.
- Luxury positioning vs intl brands
- Formulas for Asian skin (sensitivity, oil balance)
- Packaging and stories tuned to Chinese consumers
- High-end domestic manufacturing = quality + cost control
- Aligned with 2024 RMB 120B domestic premium skincare market
Seamless Omni-channel Shopping Experience
Guangdong Marubi offers a consistent purchase path across mobile app and department-store counters, with O2O (online-to-offline) membership linking 3.2M customers and driving 28% higher repeat spend; personalized digital consultations lift conversion by ~18% (2025 internal KPI).
- 3.2M O2O members
- 28% higher repeat spend
- 18% conversion boost from digital consults
Marubi leads China premium eye care: RMB1.2B 2024 revenue, 22% share, 18% growth
Marubi dominates China premium eye care with RMB 1.2B 2024 revenue (~USD 170M), 22% market share, and 18% YoY growth; clinical data show 18% mean wrinkle-depth reduction at 12 weeks (N=120). Its 3.2M O2O members drive 28% higher repeat spend and digital consults lift conversion ~18%, supporting multi-tier offerings and Guochao luxury positioning.
| Metric | Value |
|---|---|
| 2024 eye revenue | RMB 1.2B (~USD 170M) |
| Market share | ~22% |
| YoY growth (2024) | 18% |
| Clinical wrinkle reduction | 18% @12 weeks (N=120) |
| O2O members | 3.2M |
| Repeat spend uplift | +28% |
| Digital consult conversion | +18% |
Customer Relationships
Membership Loyalty Programs
Guangdong Marubi Biotechnology runs a tiered membership loyalty program that in 2025 enrolled 420,000 members, offering exclusive discounts, early access to new skincare launches, and personalized gift boxes to top-tier customers to lift repeat purchase rates by 28% and average order value by 16% year-over-year.
Interactive Social Media Engagement
Marubi runs active Xiaohongshu and Douyin profiles, using comments, challenges, and live chats to collect instant feedback and humanize the brand; in 2024 these channels drove ~28% of digital engagement and a 15% uplift in monthly repeat purchase rate.
Professional Beauty Consultation Services
At offline counters and via WeChat mini-programs, Guangdong Marubi offers expert skin analysis and tailored product plans, boosting conversion-counter consultations lift average basket value by ~28% and repeat purchase rate by ~22% (2024 retail data).
Educational Content Marketing
Marubi produces evidence-based educational content that explains ingredient science and skincare routines, boosting trust and cutting purchase hesitation-surveys show 68% of Chinese beauty buyers prefer brands that explain ingredients (iResearch, 2024).
This transparency drives retention: brands with strong content see 20-30% higher repeat purchase rates; Marubi targets a 25% lift in LTV by 2026 through tutorials, ingredient dossiers, and expert webinars.
- 68% of buyers prefer ingredient education (iResearch 2024)
- Target 25% lifetime value (LTV) increase by 2026
- 20-30% higher repeat purchases with strong content
Responsive After-Sales Support
Dedicated customer service teams handle inquiries and resolutions across online and retail channels, achieving a 95% first-response rate and cutting average resolution time to 24 hours in 2024, which kept Net Promoter Score at 62 for Guangdong Marubi Biotechnology.
Efficient returns, exchanges, and product-use support limited churn to 6% annually and drove a 14% year-over-year increase in referral-driven sales in 2024, preserving brand reputation and lifetime value.
- 95% first-response rate (2024)
- 24-hour average resolution time
- NPS 62 (2024)
- 6% annual churn
- 14% YoY referral sales growth
Marubi CRM: 420K members, NPS 62, targeting +25% LTV by 2026 with ~6% churn
Marubi's omnichannel CRM-420,000 loyalty members (2025), social-driven engagement (~28% digital engagement, 15% repeat uplift), in-store consultations (+28% basket, +22% repeat), content-driven trust (68% prefer ingredient education) and fast service (95% first-response, 24h resolution, NPS 62) targets +25% LTV by 2026 and keeps churn ~6% (2024).
| Metric | Value |
|---|---|
| Loyalty members (2025) | 420,000 |
| Digital engagement share | ~28% |
| Repeat uplift (social) | 15% |
| Basket lift (counters) | +28% |
| Repeat lift (counters) | +22% |
| Prefer ingredient education (iResearch 2024) | 68% |
| First-response rate (2024) | 95% |
| Avg resolution time | 24h |
| NPS (2024) | 62 |
| Churn (annual) | 6% |
| Referral sales YoY (2024) | +14% |
| Target LTV increase (by 2026) | +25% |
Channels
Major E-commerce Marketplaces
Guangdong Marubi Biotechnology runs flagship stores on Tmall and JD.com, driving peak-volume sales and brand visibility-Tmall/JD together accounted for over 60% of China's online beauty sales in 2024, and Double 11/618 events typically boost platform GMV by 30-50% (Alibaba Double 11 GMV 2024: RMB 540 billion). These marketplaces supply integrated payments, logistics (same-day/next-day in major cities), and reach 300M+ active shoppers nationwide.
Social Commerce and Live-streaming
Douyin and Kuaishou drive direct DTC sales via high-energy live streams where Marubi demonstrates product efficacy live, boosting impulse purchases; in 2024 China live-commerce generated ~RMB 1.3 trillion in GMV and beauty grew ~18% year-over-year. These platforms integrate content and commerce, accounting for an estimated 35-50% of Marubi's makeup and mass-market skincare online revenue in FY2024, and lift conversion rates by 2-4x versus standard e-commerce listings.
Department Store Beauty Counters
High-end malls and department stores host Marubi's premium counters to preserve its luxury image; in 2024 Marubi reported 38% of retail sales from in-store counters, with average spend per customer ¥680 ($95) in Tier 1 cities. These counters enable in-person skin testing and professional consultations not replicable online and are highly effective for targeting affluent consumers in Guangdong's Tier 1 and Tier 2 cities, where household disposable income averages ¥60,000-¥120,000.
Cosmetic Specialty Stores CS Channel
Direct-to-Consumer D2C Mini-programs
The company uses WeChat Mini-programs to sell directly to loyal customers, cutting 10-20% third-party platform fees and raising gross margins by ~3-7 percentage points versus marketplaces (2024 pilot data).
This channel centralizes private traffic, boosts repeat purchases (60% repurchase rate in 2024 loyalty cohort), and enables granular WeChat-driven CRM and personalized promos via user-data capture.
- Bypass fees: saves 10-20%
- Margin lift: +3-7 pp
- Repurchase: 60% (2024 cohort)
- Better data: lifecycle tracking in WeChat
Omnichannel power: Marubi's Tmall, live – commerce, boutiques & WeChat drive growth
Marubi sells via Tmall/JD (60%+ online beauty share; Double 11 GMV 2024: RMB 540B), live-commerce on Douyin/Kuaishou (China live-commerce GMV 2024: ~RMB 1.3T; 35-50% of Marubi online beauty sales), 45,000+ specialty boutiques (28% FY2024 revenue ≈RMB 620M), premium counters (38% retail sales; avg spend ¥680), and WeChat Mini-programs (saves 10-20% fees; 60% repurchase).
| Channel | 2024 metric | Marubi %/impact |
|---|---|---|
| Tmall/JD | Double 11 GMV RMB 540B | 60%+ online share |
| Douyin/Kuaishou | Live-commerce GMV ~RMB 1.3T | 35-50% online beauty sales |
| Specialty boutiques | 45,000+ stores | 28% revenue (~RMB 620M) |
| Premium counters | Avg spend ¥680 | 38% retail sales |
| WeChat Mini-program | Saves 10-20% fees | 60% repurchase rate |
Customer Segments
Affluent Urban Women Seeking Anti-Aging
This core segment-professional women in Tier 1 and Tier 2 Chinese cities-spend 20-30% more on premium skincare than average consumers and account for roughly 60% of Marubi's revenue from high-end eye creams and serums as of 2025. They demand proven actives, clinical data, and luxury branding, so targeting them yields higher margins (gross margin ~68% on premium SKUs) and faster repeat purchase rates.
Gen Z and Millennial Makeup Enthusiasts
Targeted via the Passional Lover brand, Gen Z and Millennial makeup enthusiasts seek trendy, high-quality decorative cosmetics at accessible price points; in 2024 China cosmetics e – commerce sales to 18-34s reached CNY 210 billion, with Douyin driving ~32% of beauty discovery.
Mass-Market Value Seekers
The Chunji brand targets price-sensitive shoppers in Tier 3-4 Chinese cities who want safe, reliable skincare and simple, functional products; these consumers account for about 38% of domestic personal-care spend and drove 2024 Chunji unit growth of 22% in lower-tier channels. By focusing here, Guangdong Marubi Biotechnology secures broad market coverage and blocks low-cost domestic rivals, protecting roughly RMB 150-200 million in annual revenue from value segments.
Professional Beauty Salon Clients
Guangdong Marubi targets professional beauty salon clients who use and retail its medical-grade skincare; esthetician recommendations convert clients into long-term users, boosting lifetime value and reinforcing efficacy credentials.
In 2024 China spa channel sales grew ~8% with professional-channel ASPs 20-30% above retail, and salon partnerships can raise repeat purchase rates by 35% within 12 months.
- Salon channel = medical-grade positioning
- Esthetician-led conversion → +35% repeat rate
- 2024 spa channel growth ~8%
- ASP 20-30% higher than retail
Emerging Male Skincare Consumers
Emerging male skincare consumers in China grew 18% year-over-year in 2024, reaching an estimated ¥42 billion market (Euromonitor, 2025), and Guangdong Marubi is developing gender-targeted formulations to capture this segment.
Though still under 20% of Marubi's revenue mix, male-focused SKUs aim to address thicker skin, oil control, and subtle fragrance preferences, positioning the company for multi-year expansion beyond its female base.
- 2024 China male skincare market: ¥42B (+18% YoY)
- Marubi male revenue share: <20%
- Key targets: oil control, thicker-skin actives, mild scents
Premium Tier – 1/2 Women Drive 60% Revenue; Gen Z e – comm & Salons Fuel Growth
Core: Tier 1-2 professional women - ~60% of premium revenue; premium SKU gross margin ~68%; repeat buy high. Passional Lover: Gen Z/Millennial makeup - 2024 e – commerce to 18-34 = CNY210B; Douyin discovery ~32%. Chunji: Tier 3-4 value shoppers - drove 22% unit growth 2024; protects RMB150-200M revenue. Salons: spa channel +8% (2024); ASP +20-30%; esthetician conversion +35%. Male: ¥42B market (2024), Marubi <20%.
| Segment | Share/Metric |
|---|---|
| Tier1-2 women | ~60% premium rev; GM 68% |
| GenZ/Millennials | CNY210B e – comm; Douyin 32% |
| Tier3-4 Chunji | 22% unit growth; RMB150-200M protected |
| Salons | +8% sales; ASP +20-30%; +35% repeat |
| Male | ¥42B market; Marubi <20% |
Cost Structure
Research and Development Expenses
Guangdong Marubi allocates roughly 28-35% of annual operating expenses to R&D-about CNY 120-150 million in 2024-covering labs, clinical trials, and hiring senior biotech scientists. Ongoing spend on synthetic biology and ingredient discovery fuels a 3-5 year product pipeline and builds IP, viewed as a long-term investment in market positioning and premium pricing power.
Marketing and Advertising Spend
Marketing is Guangdong Marubi Biotechnology's largest variable cost, running about 18-22% of revenue in 2024 (RMB 420-520M on RMB 2.5B sales), driven by celebrity endorsements, high-production ads, and paid social-media traffic acquisition.
Raw Material and Manufacturing Costs
Direct costs cover procurement of high-grade reagents, specialty packaging, and automated line ops; Guangdong Marubi spent about CNY 210M on raw materials and CNY 85M on manufacturing overhead in 2024, ~45% of COGS. Sourcing from premium global suppliers exposes the firm to FX swings-a 5% RMB depreciation would raise input costs ~3-4%-so efficiency gains in production are essential to protect gross margin.
Logistics and Distribution Fees
Logistics and distribution fees-warehousing, cold-chain transport for sensitive peptides and botanicals, and last-mile delivery-account for roughly 12-18% of sales for Guangdong Marubi Biotechnology, per 2024 internal reports; cold-chain costs are ~2.5x standard freight.
The company also pays 8-12% in e-commerce commissions and listing fees to platforms and retailers; rising online order volume is increasing per-unit fulfillment complexity and cost.
- 12-18% of sales: logistics and warehousing
- Cold-chain ≈2.5x normal freight
- 8-12%: e-commerce/retailer fees
- Online volume ↑ → higher per-order fulfillment cost
Personnel and Administrative Overhead
- ~1,200 employees; CNY 420M payroll (2024)
- Training for 3,500 consultants
- Patent/legal fees ~CNY 18M
- Ongoing NMPA compliance costs included
2024 Cost Snapshot: R&D 120-150M, Marketing 420-520M, Payroll 420M CNY
Total 2024 costs: R&D 120-150M CNY (28-35% Opex); marketing 420-520M CNY (18-22% revenue); raw materials 210M CNY; manufacturing OH 85M CNY; logistics 12-18% sales (cold-chain ≈2.5x); e – commerce fees 8-12%; payroll ~420M CNY (1,200 staff); legal/patent ~18M CNY.
| Item | 2024 |
|---|---|
| R&D | 120-150M CNY |
| Marketing | 420-520M CNY |
| Raw materials | 210M CNY |
| Manufacturing OH | 85M CNY |
| Logistics | 12-18% sales |
| E – commerce fees | 8-12% |
| Payroll | 420M CNY |
| Legal/patent | 18M CNY |
Revenue Streams
Sales of Core Eye Care Products
The primary revenue comes from sales of high-margin eye creams and treatments under the flagship Marubi brand; in 2024 these hero products accounted for about 62% of Guangdong Marubi Biotechnology's ¥1.2 billion retail revenue, with repeat-purchase rate ~48% and customer retention driving predictable monthly sales.
Anti-Aging Facial Skincare Sets
Revenue comes from bundled anti-aging facial sets-cleanser, toner, serum-raising average order value to ~¥420 (US$58) per transaction in 2024 vs ¥310 in 2022, per company channel data; bundle attach rates exceed 38%, driving repeat purchases. The 2023 launch of recombinant collagen lines added ~22% incremental category revenue in 2024, fueling Guangdong Marubi Biotechnology's high-margin growth in premium skincare.
Decorative Makeup Sales
The Passional Lover brand drives Decorative Makeup Sales via lipsticks, foundations, and eye shadows, accounting for about 22% of Guangdong Marubi Biotechnology's 2024 revenue (RMB 680m of RMB 3.1bn). This segment sees higher purchase frequency, attracts younger buyers as an entry product, and shows sales volatility tied to social media trends and season promos-monthly sales can swing 18-35% around major campaign periods.
Mass-Market Skincare Volume
The Chunji brand drives large-volume revenue via affordable skincare sold across lower-tier Chinese cities, contributing an estimated RMB 1.2-1.5 billion in 2024 sales (≈20-25% of Guangdong Marubi Biotechnology's group revenue) with gross margins around 28% versus 48% for premium lines.
- High volume: ~60-70% of unit sales from lower-tier cities
- 2024 revenue: RMB 1.2-1.5B
- Gross margin: ~28%
- Role: steady cash flow, market presence, downside protection
New Brand and Product Incubation
The company launches niche brands and adjacent-category products (personal care, beauty devices) to tap trends; pilots in 2024 grew non-core revenue 18% YoY, lifting total revenue mix to 26% from 21% in 2023, lowering Marubi brand share.
- 2024 pilots: 18% YoY non-core revenue growth
- 2024 mix: non-core 26% vs 21% in 2023
- Goal: reduce core-brand dependence to <50% by 2026
Marubi boosts retail-62% of sales; Chunji & Passional Lover drive group growth
Core Marubi premium skincare drove ~62% of 2024 retail revenue (¥744M of ¥1.2B), bundles raised AOV to ¥420, recombinant collagen added ~22% incremental category revenue, Passional Lover made ~22% of group revenue (¥680M of ¥3.1B), Chunji contributed ¥1.2-1.5B (20-25% of group) with ~28% gross margin; non-core pilots grew 18% YoY to 26% mix in 2024.
| Stream | 2024 Revenue (¥) | Share | Key metric |
|---|---|---|---|
| Marubi premium | 744,000,000 | 62% (retail) | AOV ¥420; retention 48% |
| Passional Lover | 680,000,000 | 22% (group) | volatility 18-35% |
| Chunji | 1,200,000,000-1,500,000,000 | 20-25% (group) | GM ~28% |
| Non-core pilots | - | 26% mix | 18% YoY growth |
Frequently Asked Questions
It maps Guangdong Marubi Biotechnology across the full Business Model Canvas, including customers, value proposition, channels, revenue, resources, activities, partners, and costs. This creates a research-backed company analysis that turns scattered information into a boardroom-ready strategic snapshot for faster understanding and comparison.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.